T Cell Nouveau is a clinical-stage biopharmaceutical company focused on developing innovative treatments for solid tumors using TCR-like CAR-T cell therapy. Our cutting-edge technology, developed by the Shiku laboratory at Mie University, aims to activate the immune system and effectively treat solid cancers. We believe that our unique TCR-like CAR T-cell therapy is a groundbreaking innovation that targets solid cancers where traditional CAR-T or TCR-T cell therapies have failed.

Our patented TCR-like CAR antibodies exhibit high specificity against target antigens (MAGE4 or PRAME) in peptide-HMC complexes. Additionally, our signal domain constructs help activate, maintain, and prolong T-cell function in the immunosuppressive tumor microenvironment. T Cell Nouveau is proud to deliver this groundbreaking technology from Mie University to the global medical community, as we strive to unleash the inner power of T cells to fight against cancer